Has Jeffrey Teuteberg, MD received payments from drug or device companies?

Yes. Drug and device makers reported $195,072 in general payments to Jeffrey Teuteberg, MD across 304 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Teuteberg, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Teuteberg, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Teuteberg, MD

Advanced Heart Failure and Transplant Cardiology · Stanford, CANPI 1952377582

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $123,700 of the $195,072 with a category attached, or 63.4%. 11 manufacturers reported payments, led by Abbott at 51.4% of the total.

$195,072in general payments, 2019–2025

Across 304 payments — averaging $641.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$100K
Cvrx, Inc.$45K
Medtronic$20K
Abiomed$15K
Briohealth Solutions, Inc.$6K
Paragonix Technologies, Inc.$5K
plus $5K from 5 others

$27,330in research payments, 2019–2025

Across 10 payments — averaging $2732.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Endotronix, Inc.$22K
Medtronic$5K
AstraZeneca$317

What the payments were for

Consulting fees$123,70063%
Speaking & faculty fees$44,90023%
Travel & lodging$17,3839%
Food & beverage$9,0895%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	146	$100,174
Cvrx, Inc.	85	$44,511
Medtronic(2 entities)	31	$19,513
Abiomed	16	$15,140
Briohealth Solutions, Inc.	6	$6,250
Paragonix Technologies, Inc.	10	$4,749
Takeda Pharmaceuticals U.S.A., Inc.	2	$4,200
Endotronix, Inc.	2	$186
Merck	2	$181
Edwards Lifesciences	3	$150
Daxor Corporation	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Barostim Neo System$42,156
HeartMate 3 Left Ventricular Dev$28,725
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$19,821
HeartMate 3 Left Ventricular Assist Device$16,625
HeartWare HVAD$11,670
HeartMate Touch$11,514
CardioMEMS HF System$10,165
MitraClip$7,250
BRIOVAD$6,250
Paragonix SherpaPak Cardiac Transport System$4,500
Impella$4,263
SherpaPak$2,116
Cardiovascular- Research only$1,729
HeartMate$1,000
Sherpacool$1,000
Shipper$1,000
Canister$1,000
JETi All In One Non-Sterile Kit$1,000
Arctic Front$668
MitraClip System$375

How this compares

$195,072 in reported general payments places this provider in the 85th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California →

Medicare billing

Part B allowed, 2024

$99,987

Medicare patients

489

Services billed

941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EntrestoSacubitril/Valsartan	121	$159,591
JardianceEmpagliflozin	77	$102,622
EliquisApixaban	34	$44,096
FarxigaDapagliflozin Propanediol	46	$37,667
Everolimus	13	$26,155
ZarxioFilgrastim-Sndz	11	$25,991
Sirolimus	51	$15,107
Tacrolimus	97	$6,001
Mycophenolate Mofetil	47	$4,083
Cyclosporine ModifiedCyclosporine, Modified	14	$3,215
Bumetanide	41	$2,403
Rosuvastatin Calcium	174	$1,953
Carvedilol	175	$1,724
Potassium Chloride	58	$1,442
Eplerenone	17	$1,233

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Stanford

Ronald WittelesStanford$251K
Kevin AlexanderStanford$125K
Eldrin LewisStanford$57K
Francois HaddadStanford$23K
Kiran KhushStanford$15K
Stephanie HsiaoStanford$12K
Richard WrightSanta Monica$1.7M
James Heywoodla Jolla$1.2M
Hirsch MehtaSan Diego$494K
Teresa de MarcoSan Francisco$366K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →